Clinical Trial Update: Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating whether corticosteroids can reduce infusion-related adverse events in patients with acute myeloid leukemia treated with M…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Corticosteroids (corticosteroids)
• Mylotarg (gemtuzumab ozogamicin)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Leukemia, Myelocytic, Acute, Infusions, Intravenous | Phase 4 | Status: COMPLETED